Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.41 |
| ▸ | WNT1 | P04628 | 2/20 | 0.41 |
| ▸ | TTK | P33981 | 3/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13812057 | 0.92 | ACHE (0.39) | BRAFCSNK1DWNT1TTKMAPK8 | |
| SCHEMBL4083523 | 0.85 | CSNK1D (0.44) | CSNK1DTTKLRRK2FLT3 | |
| SCHEMBL4052564 | 0.84 | CLK2 (0.52) | CSNK1DWNT1MAPK8LRRK2KDM4E | |
| SCHEMBL4084540 | 0.83 | CLK2 (0.53) | CSNK1DWNT1MAPK8LRRK2ACHE | |
| SCHEMBL13812022 | 0.83 | CSNK1D (0.41) | CSNK1DTTKMAPK8LRRK2 | |
| SCHEMBL4083165 | 0.83 | CLK2 (0.53) | CSNK1DWNT1MAPK8LRRK2ACHE | |
| SCHEMBL13812105 | 0.83 | ACHE (0.38) | BRAFCSNK1DWNT1TTKMAPK8 | |
| SCHEMBL4094402 | 0.82 | FGFR4 (0.43) | CSNK1DTTKMAPK8MAOAKDM4E | |
| SCHEMBL13812069 | 0.81 | CSNK1D (0.41) | CSNK1DTTKMAPK8LRRK2 | |
| SCHEMBL5372963 | 0.81 | CSNK1D (0.44) | CSNK1DTTKMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | BRAF 106/4885CSNK1D 702/4885WNT1 4/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | BRAF 99/4885CSNK1D 687/4885WNT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.